Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone 4 acetic acid

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 541-546

  Pruijn, Frederik B ^a   Van Daalen, Michele ^a   Holford, Nicholas H G ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

5,6 Dimethylxanthenone 4 acetic acid (DMXAA); Acidosis; Hypoxia; Melphalan; Tumour blood flow

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; MELPHALAN;

ACIDOSIS; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; DRUG TUMOR LEVEL; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PH; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL HYPOXIA; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELPHALAN; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; XANTHENES; XANTHONES;

EID: 0031016945     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050611     Document Type: Article

References (29)

1. Adams GE, Stratford IJ, Godden J, Howells N (1989) Enhancement of the antitumor effect of melphalan in experimental mice by some vasoactive agents. Int J Radiat Oncol Biol Phys 16:1137
2. Bolton MG, Hilton J, Robertson KD, Streeper RT, Colvin OM, Noe DA (1993) Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. Drug Metab Dispos 21:986
3. Chaplin DJ, Acker MD, Olive PL (1989) Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 16:1131
4. Ching LM, Joseph WR, Crosier KE, Baguley BC (1994) Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6 dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54:870
5. Ching LM, Joseph WR, Zhuang L, Baguley BC (1994) Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother Pharmacol 35:153
6. Cliffe S, Taylor ML, Rutland M, Baguley B, Hill RP, Wilson WR (1994) Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29:373
7. Edwards HS, Bremner JCM, Stratford IJ (1991) Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. Int J Radiat Biol 59:419
8. Edwards HS, Bremner JCM, Stratford IJ (1991) Induction of hypoxia by FAA and TNF: interaction with bioreductive drugs. Int J Radiat Biol 60:373
9. Evelhoch JF, Bissery MC, Chabot GG, Simpson NE, McCoy CL, Heilbrun LK, Corbett TH (1988) Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 48:4749
10. Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA (1994) Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl))alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J Med Chem 37:381
11. Hill S, Williams KB, Denekamp J (1989) Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 25:1419
12. Holford NGH (1985) MKMODEL, a modelling tool for microcomputers - a pharmacokinetic evaluation and comparison with standard computer programs (abstract). Clin Exp Pharmacol 9:95
13. Jähde E, Glüsenkamp K-H, Klünder I, Hülser DF, Tietze L-F, Rajewsky MF (1989) Hydrogen ion-mediated enhancement of cytotoxicity of bis-chloroethylating drugs in rat mammary carcinoma cells in vitro. Cancer Res 49:2965
14. Lee FYF, Workman P (1986) Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol 17:30
15. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143
16. Quinn PK, Bibby MC, Cox JA, Crawford SM (1992) The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer 66:323
17. Sansom JM, Sutton B, Reeves N, Bradley JK, Wood PJ, Bremner JCM, Adams GE, Stratford IJ (1994) Combination of photodynamic therapy (PDT) and melphalan in experimental tumors. Int J Radiat Oncol Biol Phys 29:463
18. Schwarz G (1978) Estimating the dimension of a model. Ann Stat 6:461
19. Siemann DW (1990) Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. Br J Cancer 62:348
20. Siemann DW, Chapman M, Beikirch A (1991) Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 20:287
21. Siim BG, Atwell GJ, Wilson WR (1994) Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br J Cancer 70:596
22. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ (1995) The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15:219
23. Stratford IJ, Adams GE, Godden J, Howells N, Nolan J, Timson N (1988) Potentiation of the anti-tumour effect of melphalan by the vasoactive drug, hydralazine. Br J Cancer 58:122
24. Stratford IJ, Adams GE, Bremner JCM, Cole S, Edwards HS, Robertson N, Wood PJ (1994) Manipulation and exploitation of the tumour environment for therapeutic benefit. Int J Radiat Biol 65:85
25. Sun JR, Brown JM (1989) Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res 49:5664
26. Vistica DT (1983) Cellular pharmacokinetics of the phenylalanine mustards. Pharmacol Ther 22:379
27. Wood PJ, Sansom JM, Newell K, Tannock IF, Stratford IJ (1995) Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore nigericin. Int J Cancer 60:264
28. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1989) Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 81:1005
29. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncology Res 6:79